Coloplast A/S
Coloplast A/S
Your view on CLPBY
Overview
What the company does, where it operates, and who runs it.
About Coloplast A/S
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Lars Soren Rasmussen
- Headquarters
- Holtedam 1-3, Humlebæk, DK
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Lars Soren Rasmussen
- Headquarters
- Holtedam 1-3, Humlebæk, DK
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care.
It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.
The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system.
In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution.
Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Coloplast A/S, and the rating behind it. CLPBY last traded at $7.61, 33.9× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Coloplast A/S. Starting points for Coloplast A/S: P/E 33.9, EPS $1.23, beta 0.59 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Coloplast A/S. Coloplast A/S does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Coloplast A/S. Trailing twelve-month EPS for Coloplast A/S stands at $1.23. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Coloplast A/S. Coloplast A/S has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Coloplast A/S valued side by side against its closest peers. Coloplast A/S is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Coloplast A/S, and how their positions are changing. At a $17.14B market value, institutional positions materially move Coloplast A/S's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Coloplast A/S executives and directors. Shares of Coloplast A/S have traded between $7.49 and $11.44 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Coloplast A/S. Coloplast A/S is a $17.14B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Coloplast A/S. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Coloplast A/S. Coverage tracks Coloplast A/S within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.